Acceleron Announces ACE-083 Phase 1 Results at the 14th International Congress on Neuromuscular Diseases -ACE-083 increased muscle volume of the tibialis anterior muscle by 8.9% in healthy volunteers- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced ACE-083 Phase 1 clinical trial results in healthy volunteers at the 14th International Congress on Neuromuscular Diseases in Toronto, Canada. ACE-083 is designed to selectively increase muscle mass and strength in the muscles in which the drug is...
↧